Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, Rodenhuis S, Valdés Olmos RA, Rutgers EJ, Vogel WV, Sonke GS, Vrancken Peeters MT.

Cancer Imaging. 2017 May 25;17(1):15. doi: 10.1186/s40644-017-0117-5.

2.

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling J, Rutgers EJT, Valdés Olmos RA, Sonke GS, Rodenhuis S, Vrancken Peeters MJTFD, Gilhuijs KGA.

PLoS One. 2017 May 22;12(5):e0176782. doi: 10.1371/journal.pone.0176782. eCollection 2017.

3.

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

van Ramshorst MS, van Werkhoven E, Mandjes IAM, Schot M, Wesseling J, Vrancken Peeters MTFD, Meerum Terwogt JM, Bos MEM, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS.

Eur J Cancer. 2017 Mar;74:47-54. doi: 10.1016/j.ejca.2016.12.023. Epub 2017 Feb 10.

PMID:
28335887
4.

PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease.

Teixeira SC, Koolen BB, Elkhuizen PH, Vrancken Peeters MT, Stokkel MP, Rodenhuis S, van der Noort V, Rutgers EJ, Valdés Olmos RA.

Eur J Surg Oncol. 2017 Apr;43(4):625-635. doi: 10.1016/j.ejso.2016.10.012. Epub 2016 Oct 31.

PMID:
27847287
5.

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

Loo CE, Rigter LS, Pengel KE, Wesseling J, Rodenhuis S, Peeters MJ, Sikorska K, Gilhuijs KG.

Breast Cancer Res. 2016 Aug 5;18(1):82. doi: 10.1186/s13058-016-0742-0.

6.

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

Steenbruggen TG, Linn SC, Rodenhuis S, Sonke GS.

Cureus. 2015 Dec 24;7(12):e433. doi: 10.7759/cureus.433.

7.

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF; Center for Personalized Cancer Treatment.

Breast Cancer Res. 2015 Oct 3;17(1):134. doi: 10.1186/s13058-015-0642-8.

8.

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

Jebbink M, van Werkhoven E, Mandjes IA, Wesseling J, Lips EH, Vrancken Peeters MJ, Loo CE, Sonke GS, Linn SC, Falo Zamora C, Rodenhuis S.

Breast Cancer Res Treat. 2015 Aug;153(1):145-52. doi: 10.1007/s10549-015-3510-4. Epub 2015 Jul 26.

PMID:
26210520
9.

[Recurrent upper respiratory tract infections during and after rituximab therapy].

Jacobs BA, Opdam FL, Rodenhuis S, Baars JW.

Ned Tijdschr Geneeskd. 2015;159:A8546. Review. Dutch.

PMID:
25850451
10.

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.

Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC.

Breast Cancer Res. 2014 May 15;16(3):R47. doi: 10.1186/bcr3655.

11.

Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.

Pengel KE, Koolen BB, Loo CE, Vogel WV, Wesseling J, Lips EH, Rutgers EJ, Valdés Olmos RA, Vrancken Peeters MJ, Rodenhuis S, Gilhuijs KG.

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1515-24. doi: 10.1007/s00259-014-2770-2. Epub 2014 Apr 29.

PMID:
24777490
12.

Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes.

de Ronde JJ, Bonder MJ, Lips EH, Rodenhuis S, Wessels LF.

PLoS One. 2014 Feb 18;9(2):e88551. doi: 10.1371/journal.pone.0088551. eCollection 2014.

13.

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

Rigter LS, Loo CE, Linn SC, Sonke GS, van Werkhoven E, Lips EH, Warnars HA, Doll PK, Bruining A, Mandjes IA, Vrancken Peeters MJ, Wesseling J, Gilhuijs KG, Rodenhuis S.

Br J Cancer. 2013 Dec 10;109(12):2965-72. doi: 10.1038/bjc.2013.661. Epub 2013 Oct 22.

14.

Identifying subgroup markers in heterogeneous populations.

de Ronde JJ, Rigaill G, Rottenberg S, Rodenhuis S, Wessels LF.

Nucleic Acids Res. 2013 Nov;41(21):e200. doi: 10.1093/nar/gkt845. Epub 2013 Sep 22.

15.

Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy.

Koolen BB, Valdés Olmos RA, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ, Elkhuizen PH.

Breast Cancer Res Treat. 2013 Sep;141(2):249-54. doi: 10.1007/s10549-013-2678-8. Epub 2013 Sep 4.

PMID:
24002735
16.

Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.

Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):32-40. doi: 10.1007/s00259-013-2515-7. Epub 2013 Aug 9.

PMID:
23929431
17.

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, Rodenhuis S, Wesseling J.

Breast Cancer Res Treat. 2013 Jul;140(1):63-71. doi: 10.1007/s10549-013-2620-0. Epub 2013 Jul 5.

18.

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Sonke GS, Mandjes IA, Holtkamp MJ, Schot M, van Werkhoven E, Wesseling J, Vrancken Peeters MJ, Rodenhuis S, Linn SC.

Breast J. 2013 Jul-Aug;19(4):419-26. doi: 10.1111/tbj.12124. Epub 2013 May 20.

PMID:
23682812
19.

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.

Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM.

Br J Cancer. 2013 May 28;108(10):2172-7. doi: 10.1038/bjc.2013.144. Epub 2013 Apr 4.

20.

Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.

Koolen BB, Valdés Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Vrancken Peeters MJ.

Ann Surg Oncol. 2013 Jul;20(7):2227-35. doi: 10.1245/s10434-013-2902-0. Epub 2013 Mar 1.

PMID:
23456316
21.

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.

Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Breast. 2013 Oct;22(5):691-7. doi: 10.1016/j.breast.2012.12.020. Epub 2013 Feb 12.

22.

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.

de Ronde JJ, Lips EH, Mulder L, Vincent AD, Wesseling J, Nieuwland M, Kerkhoven R, Vrancken Peeters MJ, Sonke GS, Rodenhuis S, Wessels LF.

Breast Cancer Res Treat. 2013 Jan;137(1):213-23. doi: 10.1007/s10549-012-2340-x. Epub 2012 Dec 1.

PMID:
23203637
23.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

Penel N, Demetri GD, Blay JY, Cousin S, Maki RG, Chawla SP, Judson I, von Mehren M, Schöffski P, Verweij J, Casali P, Rodenhuis S, Schütte HJ, Cassar A, Gomez J, Nieto A, Zintl P, Pontes MJ, Le Cesne A.

Ann Oncol. 2013 Feb;24(2):537-42. doi: 10.1093/annonc/mds470. Epub 2012 Nov 1.

24.

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E; I-SPY TRIAL Investigators.

Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8.

25.

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.

Koolen BB, Vrancken Peeters MJ, Wesseling J, Lips EH, Vogel WV, Aukema TS, van Werkhoven E, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1830-8. doi: 10.1007/s00259-012-2211-z. Epub 2012 Aug 16.

PMID:
22895862
26.

Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.

Koolen BB, Valdés Olmos RA, Elkhuizen PH, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ.

Breast Cancer Res Treat. 2012 Aug;135(1):231-40. doi: 10.1007/s10549-012-2179-1. Epub 2012 Jul 28.

PMID:
22872522
27.

Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.

Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.

Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

PMID:
22357256
28.

[Centralising cancer treatment: a good idea].

Rodenhuis S.

Ned Tijdschr Geneeskd. 2011;155(45):A3813. Dutch.

PMID:
22085567
29.

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.

Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AM, Imholz AL, Wessels LF, Wesseling J, Nederlof PM, Rodenhuis S.

Breast Cancer Res. 2011 Oct 27;13(5):R107. doi: 10.1186/bcr3049.

30.

18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.

Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Breast Cancer Res Treat. 2012 Jan;131(1):117-26. doi: 10.1007/s10549-011-1767-9. Epub 2011 Sep 21.

PMID:
21935602
31.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T.

J Clin Oncol. 2011 Aug 20;29(24):3214-23. doi: 10.1200/JCO.2010.32.5910. Epub 2011 Jul 18.

32.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Vincent A, Vrancken Peeters MT, Nederlof PM, Wesseling J, Rodenhuis S.

Breast Cancer Res Treat. 2012 Feb;131(3):827-36. doi: 10.1007/s10549-011-1488-0. Epub 2011 Apr 7.

PMID:
21472434
33.

An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.

Giesen E, Mager A, van Tinteren H, Rodenhuis S, Kerst JM.

Urol Oncol. 2013 Jan;31(1):110-4. doi: 10.1016/j.urolonc.2010.10.006. Epub 2011 Apr 1.

PMID:
21458311
34.

Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.

Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, Gilhuijs KG.

J Clin Oncol. 2011 Feb 20;29(6):660-6. doi: 10.1200/JCO.2010.31.1258. Epub 2011 Jan 10.

PMID:
21220595
35.

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EG, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC.

Ann Oncol. 2011 Jul;22(7):1561-70. doi: 10.1093/annonc/mdq624. Epub 2010 Dec 6.

36.

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MT, van de Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S.

Ann Oncol. 2011 Apr;22(4):870-6. doi: 10.1093/annonc/mdq468. Epub 2010 Oct 11.

PMID:
20937646
37.

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Straver ME, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Wesseling J, Russell NS, Oldenburg HS, Antonini N, Vrancken Peeters MT.

Ann Surg Oncol. 2010 Sep;17(9):2411-8. doi: 10.1245/s10434-010-1008-1. Epub 2010 Apr 6.

39.

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy.

Rodenhuis S, Mandjes IA, Wesseling J, van de Vijver MJ, Peeters MJ, Sonke GS, Linn SC.

Ann Oncol. 2010 Mar;21(3):481-7. doi: 10.1093/annonc/mdp348. Epub 2009 Aug 28.

PMID:
19717533
40.

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S.

Breast Cancer Res Treat. 2010 Jan;119(1):119-26. doi: 10.1007/s10549-009-0499-6. Epub 2009 Aug 8.

PMID:
19669409
41.

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer.

Straver ME, Rutgers EJ, Russell NS, Oldenburg HS, Rodenhuis S, Wesseling J, Vincent A, Peeters MT.

Eur J Cancer. 2009 Sep;45(13):2284-92. doi: 10.1016/j.ejca.2009.04.029. Epub 2009 May 20.

PMID:
19464164
42.

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.

Straver ME, Glas AM, Hannemann J, Wesseling J, van de Vijver MJ, Rutgers EJ, Vrancken Peeters MJ, van Tinteren H, Van't Veer LJ, Rodenhuis S.

Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub 2009 Feb 13.

PMID:
19214742
43.

Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.

Ekhart C, Rodenhuis S, Beijnen JH, Huitema AD.

Ther Drug Monit. 2009 Feb;31(1):95-103. doi: 10.1097/FTD.0b013e318194e484.

PMID:
19155964
44.

Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.

Gast MC, van Tinteren H, Bontenbal M, van Hoesel RQ, Nooij MA, Rodenhuis S, Span PN, Tjan-Heijnen VC, de Vries EG, Harris N, Twisk JW, Schellens JH, Beijnen JH.

BMC Cancer. 2008 Dec 24;8:389. doi: 10.1186/1471-2407-8-389.

45.

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.

Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17.

46.

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].

Straver ME, van Adrichem JC, Rutgers EJ, Rodenhuis S, Linn SC, Loo CE, Gilhuijs KG, Oldenburg HS, Wesseling J, Russell NS, Antonini N, Vrancken Peeters MT.

Ned Tijdschr Geneeskd. 2008 Nov 15;152(46):2519-25. Dutch.

PMID:
19055260
47.

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Ekhart C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD.

Cancer Chemother Pharmacol. 2009 Jun;64(1):115-22. doi: 10.1007/s00280-008-0856-x. Epub 2008 Nov 7.

PMID:
18989671
48.

Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.

Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, Peeters MJ, Gilhuijs KG.

AJR Am J Roentgenol. 2008 Nov;191(5):1331-8. doi: 10.2214/AJR.07.3567.

PMID:
18941065
49.

Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.

Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.

Pharmacogenet Genomics. 2008 Nov;18(11):1009-15. doi: 10.1097/FPC.0b013e328313aaa4.

PMID:
18854779
50.

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.

Cancer Treat Rev. 2009 Feb;35(1):18-31. doi: 10.1016/j.ctrv.2008.07.003. Epub 2008 Sep 3. Review.

PMID:
18771857

Supplemental Content

Loading ...
Support Center